Epistem’s IBD preclinical platform is an integrated offering combining a comprehensive range of models with a high level of IBD expertise. Epistem has a track record of delivering high quality preclinical results across a wide range of pharmaceutical clients.

Established models

• DSS
• TNBS
• IL-10
• Combination Studies (synergistic response in combination with current gold standards)

Currently extending Epistem's range of models to include:

• Chronic DSS
• T-cell transfer (in development)
• Oxazalone (in development)

Typical parameters measured:

• Weight
• Diarrhoea severity, faecal blood and overt rectal bleeding
• Colon weight/length
• Colitis severity score (histological)
• Extensive histometric severity score
• Myeloperoxidase assay
• Gene expression analysis
• Immunohistochemistry